Xbrane Biopharma AB (XBRANE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xbrane Biopharma AB (XBRANE) has a cash flow conversion efficiency ratio of -0.121x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-67.56 Million ≈ $-7.27 Million USD) by net assets (Skr560.65 Million ≈ $60.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Xbrane Biopharma AB - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Xbrane Biopharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Xbrane Biopharma AB for a breakdown of total debt and financial obligations.
Xbrane Biopharma AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xbrane Biopharma AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SABUY TECHNOLOGY
BK:SABUY-R
|
N/A |
|
Tevogen Bio Holdings Inc
NASDAQ:TVGN
|
0.265x |
|
SCGM Bhd
KLSE:7247
|
-0.031x |
|
Cleanspace Holdings Ltd
AU:CSX
|
0.133x |
|
KONG SUN (BL25000)
F:KOJ5
|
N/A |
|
Daedong Steel Co. Ltd
KQ:048470
|
-0.105x |
|
Hove AS
CO:HOVE
|
-0.033x |
|
Asia Technology Co Ltd
KQ:050860
|
0.044x |
Annual Cash Flow Conversion Efficiency for Xbrane Biopharma AB (2013–2025)
The table below shows the annual cash flow conversion efficiency of Xbrane Biopharma AB from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Xbrane Biopharma AB market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr560.65 Million ≈ $60.34 Million |
Skr-250.69 Million ≈ $-26.98 Million |
-0.447x | +30.27% |
| 2024-12-31 | Skr208.54 Million ≈ $22.44 Million |
Skr-133.73 Million ≈ $-14.39 Million |
-0.641x | +72.98% |
| 2023-12-31 | Skr171.34 Million ≈ $18.44 Million |
Skr-406.68 Million ≈ $-43.77 Million |
-2.374x | -420.07% |
| 2022-12-31 | Skr424.89 Million ≈ $45.72 Million |
Skr-193.92 Million ≈ $-20.87 Million |
-0.456x | +10.27% |
| 2021-12-31 | Skr431.74 Million ≈ $46.46 Million |
Skr-219.61 Million ≈ $-23.63 Million |
-0.509x | +45.02% |
| 2020-12-31 | Skr257.71 Million ≈ $27.73 Million |
Skr-238.41 Million ≈ $-25.66 Million |
-0.925x | -14.76% |
| 2019-12-31 | Skr184.32 Million ≈ $19.84 Million |
Skr-148.59 Million ≈ $-15.99 Million |
-0.806x | -243.37% |
| 2018-12-31 | Skr83.07 Million ≈ $8.94 Million |
Skr46.71 Million ≈ $5.03 Million |
0.562x | +234.89% |
| 2017-12-31 | Skr88.41 Million ≈ $9.51 Million |
Skr-36.85 Million ≈ $-3.97 Million |
-0.417x | -13.44% |
| 2016-12-31 | Skr107.30 Million ≈ $11.55 Million |
Skr-39.43 Million ≈ $-4.24 Million |
-0.367x | -40.93% |
| 2015-12-31 | Skr47.51 Million ≈ $5.11 Million |
Skr-12.39 Million ≈ $-1.33 Million |
-0.261x | +38.46% |
| 2014-12-31 | Skr6.30 Million ≈ $677.75K |
Skr-2.67 Million ≈ $-287.16K |
-0.424x | -67.55% |
| 2013-12-31 | Skr8.69 Million ≈ $935.17K |
Skr-2.20 Million ≈ $-236.48K |
-0.253x | -- |
About Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularizati… Read more